CMS Energy(US:CMS) Prnewswire·2024-10-10 12:00Core Insights - Akebia Therapeutics announced that its product Vafseo (vadadustat) has been approved for the Transitional Drug Add-On Payment Adjustment (TDAPA) by the Center for Medicare & Medicaid Services (CMS), effective January 1, 2025, providing two years of reimbursement in addition to the ESRD bundled rate for dialysis organizations [1][2][3] Group 1: Product and Approval Details - Vafseo is indicated for the treatment of anemia due to chronic kidney disease in adults who have been on dialysis for at least three months and was approved by the FDA in March 2024 [1][5][6] - A Level II Healthcare Common Procedure Coding System (HCPCS) code has been assigned to Vafseo to facilitate billing for Medicare enrollees [2][3] - The product is expected to be available in the market starting January 2025 [1][3] Group 2: Commercial Strategy and Engagement - Akebia is actively engaging with dialysis organizations to facilitate access to Vafseo and plans to interact with nephrologists and healthcare providers at the upcoming American Society of Nephrology conference [3] - The TDAPA status and billing code are seen as significant milestones in the commercial launch of Vafseo, aimed at driving usage and demand [3] Group 3: Company Overview - Akebia Therapeutics, founded in 2007 and headquartered in Cambridge, Massachusetts, focuses on improving the lives of individuals affected by kidney disease [4]